A T1D traveler with 40 countries under her belt sets the record straight.
In the 1980 s, researchers identified GLP-1 in the gut and discovered its role in enhancing insulin release while simultaneously suppressing glucagon secretion [5]
Fatigue in the early weeks is actually a sign the medication is doing its job your appetite is suppressed, your calorie intake has dropped, and your body is adjusting
In this context, therapies such as GLP-1RAs may represent a complementary strategy aimed at modulating both metabolic dysfunction and inflammation, thereby optimizing disease control and improving long-term outcomes in PsA
They also contain many vitamins and minerals that can support overall health
While Semaglutide GLP-1 is generally considered safe and effective for most individuals with obesity, there are certain groups of people who may not be able to use Semaglutide GLP-1 due to potential risks and contraindications